Accendra Health Inc/Va/ACH

Accendra Health’s latest 10-Q, filed on 8 May 2026, shows a company that collected $627.8 million in revenue for the quarter to 31 March 2026 but still managed to post a $6.5 million net loss, leaving shareholders with a $464.8 million deficit in equity. The operating income of $17.1 million was the only sliver of good news, and even that sat against $170 million of cash burned in operating activities over the previous year. Cash on hand was $336.9 million, which sounds healthier than it feels once you remember the firm is haemorrhaging cash faster than a Sunday barbecue patient on portable oxygen.

Accendra Health, formerly known as Owens & Minor, bills itself in the newsroom as a leading nationwide provider of products, technology, and services that ‘support health beyond the hospital.’ In plain terms, that means selling home medical gear and services to 85% of insured Americans through its Apria and Byram Healthcare brands. The brands are real; the economics are still finding their feet. The company’s overview page promises ‘peace of mind’ and ‘confidence,’ but the balance sheet reads more like a DME supplier that forgot to invoice the oxygen.

The filings are unambiguous. Revenue was $627.8 million in the quarter to 31 March 2026. Net income was -$6.5 million. Operating income was $17.1 million. Cash and cash equivalents were $336.9 million. Stockholders’ equity attributable to the parent was -$464.8 million. Net cash used in operating activities was -$170.0 million over the year to 30 September 2025. Capital expenditure on property, plant, and equipment was $41.6 million. Inventory stood at $65.3 million, down $9.2 million from the prior period. Diluted earnings per share were -$0.08 on 76.4 million diluted shares. All figures are drawn from the 10-Q for the quarter ended 31 March 2026.

If you want to see the company’s own words on separation and capital-raising, the S-3 filed on 15 July 2026 is where the board explains its push to unlock value post-spin. The document is polite, optimistic, and light on the kind of arithmetic that might keep a treasurer awake at night. The 8-K filed on 25 June 2026 confirms the board’s approval of a new share repurchase programme, but the programme’s size and timing depend on market conditions and available capital-so far, the market has been conditioning away. The 8-K filed on 15 June 2026 reports the resignation of a director, a reminder that boards are as stable as the cash that funds them.

Accendra’s investor-relations site points to the Apria and Byram Healthcare brands as the public face of the business. Apria and Byram sell home healthcare equipment and related services to improve outcomes and affordability, and they reach roughly 85% of insured Americans. The customer base is real; the cash conversion cycle is less so. The company’s overview page promises ‘peace of mind,’ ‘confidence,’ and a ‘commitment to connecting patients, providers, and insurers,’ but the filings show a company still learning how to collect the cheque without the oxygen running out first.

For a live price and chart route, TradingView’s ACH chart on the Nasdaq Composite is the cleanest public feed, but remember that Accendra’s primary listing is on the Nasdaq and the evidence above is drawn from US filings and company sources. The chart will show price and volume; the filings will show why the company’s equity story is still in draft. There is no evidence in the supplied sources for any analyst estimates, valuation commentary, or forward-looking metrics.

What changed this week: the S-3 filing on 15 July 2026 signals the board’s intent to separate certain assets and raise capital, but the filing does not specify amounts or timing. The 10-Q for the quarter to 31 March 2026 is the latest filed financial update and shows continued cash burn and an equity deficit. No new product launches, sales milestones, or approvals appear in the supplied news or filings since May 2026. The ‘Our Brands’ page and the company overview remain the only public-facing product rails; neither contains revenue, margin, or customer-acquisition figures.